Clinical Trial Details

< Previous Trial     Next Trial >
Study ID P10-3
Candice McCoy, MD,   Dendreon
Title A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Conditions Advanced Prostate Cancer
Prostatic Neoplasms
Interventions Biological: sipuleucel-T
Phase N/A
Purpose The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Male
Accepts Healthy Volunteers:  No
Inclusion Criteria:
  • subjects must be at least 18 years of age
  • subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment
  • subjects must understand and sign an informed consent form
Exclusion Criteria:
  • none
Study Location
Birmingham Hematology and Oncology Associates, LLC
Bessemer, Alabama, 35022
Contact N/A

Information objtained from, on 9/20/2014. For additional information about this and other clinical trials, visit
Please refer to this study by its identifier: NCT01306890

Back to Search Results